Psoriatic arthritis management update - biotherapeutic options.
Saber, Tajvur P Veale, Douglas J
Saber, Tajvur P
Veale, Douglas J
Author
Advisors
Editors
Other Contributors
Date
2012-02-01T10:30:11Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Arthritis, Psoriatic/*drug therapy
Biological Factors/*therapeutic use
Clinical Trials as Topic
Humans
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Biological Factors/*therapeutic use
Clinical Trials as Topic
Humans
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy (SpA) occurring in up to 30% of patients with psoriasis. It has a wide variation of annual incidence (median 6.4, range 0.1-3.1 per 10(5) people), based on analysis of 13 incidence and prevalence reviews published between 1987 and December 2006. Conventional treatments with antiinflammatory and disease modifying or antirheumatic drugs are not efficacious in all patients, in particular those with axial disease. This review examines new pharmacological developments in the treatment of PsA with a focus on biologic therapies.
Language
eng
Citation
ISSN
0380-0903 (Print)
0380-0903 (Linking)
0380-0903 (Linking)
eISSN
ISBN
DOI
10.3899/jrheum.090229
PMID
19661546